SANGAMO THERAPEUTICS INC (SGMO) Stock Income Statement
NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 52.77M | 176.23M | 111.30M | 110.70M | 118.20M | |||
| Minority Interest Expense | N/A | 0.00 | 0.00 | 0.00 | 100.00K | |||
| Operating Expenses | 222.17M | 278.82M | 312.60M | 294.00M | 247.70M | |||
| Research and Development | 165.44M | 221.66M | 249.90M | 230.80M | 180.60M | |||
| Selling, General, and Administrative Expenses | 56.73M | 57.17M | 62.70M | 63.20M | 67.10M | |||
| Operating Income | -169.40M | -102.59M | -201.30M | -183.30M | -129.60M | |||
| Interest Income/Expense | 7.72M | 11.10M | 9.40M | 5.30M | 8.80M | |||
| Non Recurring Items | -22.17M | -171.41M | N/A | N/A | N/A | |||
| Income Before Taxes | -183.84M | -262.90M | -191.80M | -178.00M | -120.80M | |||
| Income Tax | 86.00K | -5.07M | 400.00K | 300.00K | 300.00K | |||
| Net Income | -183.93M | -257.83M | -192.30M | -178.30M | -121.00M | |||
| EBITDA | -163.67M | -87.53M | -189.20M | -173.90M | -123.90M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.98 | -1.48 | -1.25 | -1.23 | -0.90 | |||
| Non GAAP EPS | -0.75 | -1.47 | -1.25 | -1.24 | -0.93 | |||
| Statistics | ||||||||
| Profit Margin | -348.54% | -146.30% | -172.78% | -161.07% | -102.37% | |||
| Operating Profit Margin | -321.00% | -58.21% | -180.86% | -165.58% | -109.64% | |||
All data in USD